Epilepsy Research
Volume 21, Issue 3 , Pages 227-230, July 1995

Retrospective study of vigabatrin and psychiatric behavioural disturbances

The David-Lewis Centre for Epilepsy, Mill Lane, Warford, Near Alderley Edge, Cheshire SK9 7UD, UK

Received 18 January 1995; received in revised form 28 March 1995; accepted 29 March 1995.

Abstract 

Vigabatrin (VGB) is an effective add-on anti-epileptic drug. The major serious adverse drug reactions (ADRs) are behavioural and psychiatric disturbances. This study does not support the view that a previous history of behavioural and psychiatric features increases the risk of behavioural/psychiatric ADRs (relative risk 1.23, 95% CI 0.57-2.66, P = 0.61). The results suggest that a low starting does of vigabatrin does not reduce the risk of psychiatric and behavioural ADRs (P = 0.31) or prevent a more overt psychotic reaction from occurring.

Keywords:  Vigabatrin, Adverse drug reactions, Retrospective study

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: 0920-1211(95)00022-3

Epilepsy Research
Volume 21, Issue 3 , Pages 227-230, July 1995

Article Tools